Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)

Table 7 Mortality in primary bacteremia patients receiving C/T

Author, year	Study design	Pathogen type	Antibiotic resistance	Outcome definition	Time point	% (n/N) Reporting mortality
Retrospective cohort studies
Elabor et al., 2018 [15]	Retrospective cohort	Pseudomonas: 100% (not further specified)	MDR infection: 100%	–	30 days	0% (0/4)^a
Gallagher et al., 2018 [17]	Retrospective cohort	Pseudomonas: 100% (not further specified)	MDR infection: 100%	Defined as patients who died in the hospital after 30 days	30 days	0% (0/6)
Haidar et al., 2017 [18]	Retrospective cohort (single patient)	P. aeruginosa: 100%	MDR infection: 100%	Defined as P. aeruginosa if the patient died with signs and symptoms of infection, microbiologic or histological evidence of an active P. aeruginosa infection, and if other potential causes of death were reasonably excluded	90 days	0% (0/1)^b
King et al. et al., 2018 [11]	Retrospective cohort	Pseudomonas: 100% (not further specified)	MDR infection: 100%	In-hospital mortality	–	0% (0/7)^c
King et al. et al., 2018 [11]	Retrospective cohort	Pseudomonas: 100% (not further specified)	MDR infection: 100%	–	30 days	14.0% (1/7)

MDR, Multi drug resistant
^aMortality not explicitly reported, but all 4 patients were reported to survive. This value may need to be evaluated with caution when considering timings for evaluating in-hospital mortality (NR for bacteremia patients). For the overall group of patients, 17/65 (26.1%) of patients died in hospital, yet 56/65 (86.1%) of patients survived to 30 days (indicating that only 9 patients died)
^bDied within 90 days (Not attributable)
^cIn-hospital mortality

ISSN: 1476-0711